Dapagliflozin (DAPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is
well-recognized for its therapeutic benefits in type 2 diabetes (T2D) and cardiovascular …
… mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells
Published: 10/31/2024